Horizon Therapeutics Public Limited Company
Simbolis: HZNP
NASDAQ
116.3
USDRinkos kaina šiandien
62.1155
P/E santykis
0.5721
PEG koeficientas
26.63B
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Horizon Therapeutics Public Limited Company (HZNP) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 9289.14 | 2352.8 | 1580.3 | 2079.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 114.75 | 28.2 | 26.5 | 18.4 | |||||||||||||||
balance-sheet.row.net-receivables | 2670.21 | 676.3 | 632.8 | 659.7 | |||||||||||||||
balance-sheet.row.inventory | 694.64 | 169.6 | 225.7 | 75.3 | |||||||||||||||
balance-sheet.row.other-current-assets | 1549.86 | 449.3 | 360.9 | 255.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 14589.66 | 3652.8 | 2799.8 | 3070.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1376.4 | 340.5 | 292.3 | 189 | |||||||||||||||
balance-sheet.row.goodwill | 4042.15 | 1010.5 | 1066.7 | 413.7 | |||||||||||||||
balance-sheet.row.intangible-assets | 13725.2 | 3474.8 | 3840.1 | 1783 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 17767.35 | 4485.3 | 4906.8 | 2196.6 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.tax-assets | 1842.66 | 431.8 | 538.1 | 560.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 858.6 | 204.1 | 140.7 | 55.7 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 21845.01 | 5461.8 | 5878 | 3002.2 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 36434.67 | 9114.6 | 8677.7 | 6072.6 | |||||||||||||||
balance-sheet.row.account-payables | 350.07 | 155.8 | 30.1 | 37.7 | |||||||||||||||
balance-sheet.row.short-term-debt | 64 | 16 | 16 | 0 | |||||||||||||||
balance-sheet.row.tax-payables | 172.07 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 10181.67 | 2546.8 | 2555.2 | 1003.4 | |||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1263.5 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 3198.24 | 777.3 | 840.4 | 838 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 12309.97 | 3093.3 | 3118.8 | 1171.5 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-liab | 15922.29 | 4042.4 | 4005.3 | 2047.3 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0.09 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.retained-earnings | 2612.75 | 590 | 318.6 | -215.9 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 48.28 | 12.5 | -15 | -0.1 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 17851.26 | 4469.6 | 4368.8 | 4241.4 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 20512.38 | 5072.2 | 4672.4 | 4025.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 36434.67 | 9114.6 | 8677.7 | 6072.6 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-equity | 20512.38 | 5072.2 | 4672.4 | 4025.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 36434.67 | - | - | - | |||||||||||||||
Total Investments | 114.75 | 28.2 | 26.5 | 18.4 | |||||||||||||||
balance-sheet.row.total-debt | 10245.67 | 2562.8 | 2571.2 | 1003.4 | |||||||||||||||
balance-sheet.row.net-debt | 986.05 | 210 | 990.9 | -1076.5 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 438 | 521.5 | 534.5 | 389.8 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 389 | 390.4 | 353.8 | 279.5 | |||||||||||||||
cash-flows.row.deferred-income-tax | -39.11 | 49.8 | -101 | -33.5 | |||||||||||||||
cash-flows.row.stock-based-compensation | 208.04 | 182.1 | 219.1 | 146.6 | |||||||||||||||
cash-flows.row.change-in-working-capital | -5.32 | -12 | -61.7 | -345.7 | |||||||||||||||
cash-flows.row.account-receivables | -44.08 | -43.5 | 34.8 | -251.2 | |||||||||||||||
cash-flows.row.inventory | 33.32 | 56.1 | 1.3 | -21.5 | |||||||||||||||
cash-flows.row.account-payables | 63.98 | 122.2 | -12.2 | 16 | |||||||||||||||
cash-flows.row.other-working-capital | -58.54 | -146.9 | -85.6 | -89.1 | |||||||||||||||
cash-flows.row.other-non-cash-items | 50.03 | 126 | 90.7 | 118.9 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1040.64 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -134.52 | -126.3 | -126.2 | -199.9 | |||||||||||||||
cash-flows.row.acquisitions-net | 28.45 | -3.1 | -2845.3 | -262.3 | |||||||||||||||
cash-flows.row.purchases-of-investments | -8.57 | -9.2 | -24.7 | -13.3 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0.22 | 4.6 | -49.6 | -30 | |||||||||||||||
cash-flows.row.other-investing-activites | -28.45 | 0 | 51.6 | 41.4 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -142.87 | -134 | -2994.1 | -464.1 | |||||||||||||||
cash-flows.row.debt-repayment | -16 | -16 | -12 | -1.7 | |||||||||||||||
cash-flows.row.common-stock-issued | 34.99 | 30.3 | 0 | 919.8 | |||||||||||||||
cash-flows.row.common-stock-repurchased | -250.08 | -250.1 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.other-financing-activites | -103.35 | -112.2 | 1482.1 | -13.5 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -334.43 | -348 | 1470.1 | 904.6 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 8.77 | -2.5 | -10.6 | 7.2 | |||||||||||||||
cash-flows.row.net-change-in-cash | 572.11 | 773.4 | -499.3 | 1003.4 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 9278.67 | 2357.6 | 1584.2 | 2083.5 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 8706.56 | 1584.2 | 2083.5 | 1080 | |||||||||||||||
cash-flows.row.operating-cash-flow | 1040.64 | 1257.8 | 1035.3 | 555.7 | |||||||||||||||
cash-flows.row.capital-expenditure | -134.52 | -126.3 | -126.2 | -199.9 | |||||||||||||||
cash-flows.row.free-cash-flow | 906.13 | 1131.6 | 909.1 | 355.8 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3644.41 | 3629 | 3226.4 | 2200.4 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 903.44 | 920.2 | 794.5 | 532.7 | |||||||||||||||
income-statement-row.row.gross-profit | 2740.97 | 2708.8 | 2431.9 | 1667.7 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 515.77 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 770.1 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0.4 | -5.6 | 1.8 | 3.4 | |||||||||||||||
income-statement-row.row.operating-expenses | 2173.34 | 1979 | 1878.4 | 1182.6 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 3076.78 | 2899.2 | 2672.9 | 1715.3 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.interest-expense | 68.68 | 83.7 | 81.1 | 59.6 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -55.41 | -90.5 | -80.3 | -88.4 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0.4 | -5.6 | 1.8 | 3.4 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -55.41 | -90.5 | -80.3 | -88.4 | |||||||||||||||
income-statement-row.row.interest-expense | 68.68 | 83.7 | 81.1 | 59.6 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 441.47 | 497.2 | 365.9 | 278 | |||||||||||||||
income-statement-row.row.ebitda-caps | 957.03 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 513.37 | 617.4 | 543.1 | 490 | |||||||||||||||
income-statement-row.row.income-before-tax | 443.86 | 526.9 | 462.8 | 401.6 | |||||||||||||||
income-statement-row.row.income-tax-expense | 5.86 | 5.5 | -71.7 | 11.8 | |||||||||||||||
income-statement-row.row.net-income | 438 | 521.5 | 534.5 | 389.8 |
Dažnai užduodami klausimai
Kas yra Horizon Therapeutics Public Limited Company (HZNP) bendras turtas?
Horizon Therapeutics Public Limited Company (HZNP) bendras turtas yra 9114616000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 1777018000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.752.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 3.873.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.120.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.141.
Kas yra Horizon Therapeutics Public Limited Company (HZNP) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 521482000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 2562837000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 1979014000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 2464623000.000.